Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080999 | 1.00 | GPR119 (0.34) | GPR119NR1H2ABCB1HSD11B1NR1H3 | |
| SCHEMBL5434124 | 1.00 | GPR119 (0.34) | GPR119NR1H2ABCB1HSD11B1NR1H3 | |
| SCHEMBL8690955 | 1.00 | GPR119 (0.34) | GPR119NR1H2ABCB1HSD11B1NR1H3 | |
| SCHEMBL1526484 | 0.87 | NR1H2 (0.35) | NR1H2ABCB1PARP1 | |
| SCHEMBL4560424 | 0.87 | PPM1D (0.32) | — | |
| SCHEMBL24894673 | 0.87 | NR1H2 (0.35) | GPR119NR1H2ABCB1PARP1 | |
| SCHEMBL9383410 | 0.87 | NR1H2 (0.35) | GPR119NR1H2ABCB1PARP1 | |
| SCHEMBL1526483 | 0.87 | NR1H2 (0.35) | NR1H2ABCB1PARP1 | |
| SCHEMBL24826386 | 0.87 | NR1H2 (0.35) | GPR119NR1H2ABCB1PARP1 | |
| SCHEMBL2387181 | 0.87 | NR1H2 (0.35) | GPR119NR1H2ABCB1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912994-B1 | ADENINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-7977343-B2 | Adenine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20100160352-A1 | ADENINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-06-24 | — | — | US | disclosed |
| WO-2009026197-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160352-A1 | ADENINE DERIVATIVES | HSP90AA1, TRAP1, HSP90AB1 | GPR119 2275/4885NR1H2 1011/4885ABCB1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.